Reboxetine: additional benefits to the depressed patient.

摘要: Reboxetine is a new selective noradrenaline reuptake inhibitor that has been shown to be effective in both the short-(4-8 weeks) and long-term (up 12 months) treatment of depression. Four positive placebo-controlled studies showed reboxetine have significant antidepressant efficacy; response rate (> or = 50% decrease HAM-D total score) with ranging from 56-74%. Comparator-controlled trials at least as efficacious imipramine desipramine adults elderly patients. also fluoxetine overall depressed population. However, subset analysis significantly superior severely advantages over terms social functioning, positively affecting patients' self perception motivation towards action. The therapeutic effect maintained for up 1 year. During therapy, 78% patients receiving were remission last assessment compared only 45% placebo group. Fewer reboxetine-treated relapsed (22%) those (56%). In summary, short- depression, traditional tricyclic drugs serotonin inhibitors. additional benefits offered by patient include treatment, efficacy all grades depression (including severe cases) and, importantly, specific on functioning. These make favourable choice management